Drugs / GDC-6988
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06603246 | Nov 2024 → Nov 2027 expected | bronchiectasis | Genentech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDC-6988 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06603246 ↗ |
| Route | Inhaled | “GDC-6988 will be administered using a dry powder inhalation (DPI) device.” NCT06603246 ↗ |